Page last updated: 2024-10-30

losartan and Diffuse Cutaneous Systemic Sclerosis

losartan has been researched along with Diffuse Cutaneous Systemic Sclerosis in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"The current case indicates that late recurrences of scleroderma renal crisis are possible in renal transplant recipients and that angiotensin-converting enzyme inhibitors, rather than angiotensin II receptor blockers, may be the superior drugs for such patients."1.33Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. ( Cheung, WY; Gibson, IW; Jeffery, J; Karpinski, M; Rush, D, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheung, WY1
Gibson, IW1
Rush, D1
Jeffery, J1
Karpinski, M1

Other Studies

1 other study available for losartan and Diffuse Cutaneous Systemic Sclerosis

ArticleYear
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert

2005